Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's
Disease. Dementia is defined as a serious loss in cognitive ability due to damages or disease
in the brain beyond what is normal aging. With Lewy Body Dementia, protein deposits, or Lewy
Bodies, accumulate in nerve cells throughout the brain, affecting motor control, memory and
thinking. LBD can also form with the progression of Parkinson's disease (PD). PD is a
degenerative nervous system disorder that affects movement ability. Using more sensitive MRI
imaging techniques the investigators are attempting to see if disease progression can be
monitored more closely. At the same time, the study medication Memantine will be compared to
a placebo to determine if it can be used to slow the progression of PD. The purpose of this
study is to assess if disease progression can be better monitored through brain imaging and
if Memantine will help slow disease progression.